Lundbeck Acquires Prexton Therapeutics

Lundbeck and Prexton Therapeutics BV (Prexton) have signed an agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100 million upfront plus €805 million in development and sales milestones.

Because of the acquisition, Lundbeck will obtain global rights for Prexton’s foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). 

“We are very excited to be working with Lundbeck, a company with a strong history and focus on diseases of the central nervous system,” said François Conquet, Ph.D., founder and chief executive officer, Prexton. “Lundbeck shares our vision for the development of foliglurax to help patients living with Parkinson’s disease.”